The study found that in 8 weeks, benfotiamine (a thiamine derivative with better biodisponibility) enhanced spatial memory and reduced amyloid plaque numbers and phosphorylated tau levels in mice brains, which suggests that it can be beneficial for clinical Alzheimer’s diseasetreatment. The gene discussed is MAPT; the disease is amyloidosis.